| |
 |
Robert J. Manning FM, RNG
Staff
Title: Senior Project Leader, Bing Center Laboratory
Hospital: Dana Farber Cancer Institute
Email: robert_manning@dfci.harvard.edu
Address: 44 Binney St.
Boston, MA 02115
USA
|
|
While walking the hallways of Dana Farber Cancer Institute, one is likely to meet my father, the well-loved volunteer Bob Manning. Retired from 35 years of service at the Polaroid Corporation as a quality control superviser, Bob was intimately introduced to DFCI when his wife of 34 years was diagnosed with cancer. Amply impressed with the care the staff provided to his family, he began volunteering part time in the National Marrow Donor Program.
This dedicated and out-going chap is quite well rounded. Bob served in the United States Marine Corps (1959-1966) and studied engineering at Northeastern University. Ever energetic, he was honored to bear the torch of the 2002 Olympic Torch Relay Team, through Plymouth, Massachusetts as the torch made its way across the country. He is extremely passionate about his Irish heritage and is also an especially proud father and grandfather.
Involving himself in other areas of the Institute, Bob has completed the Pan-Massachusetts Challenge fundraising bike-a-thon 5 times on the platelet peddler team, has been a member of the Kraft Family Blood Bank's "Team 20" having donated platlets over twenty times a year, and is a national and international peripheral blood stem cell & bone marrow courier. Committed to the good of the Institute, Bob is now a full time volunteer, currently splitting his time between the Gastrointestinal Oncology Center and the Waldenström’s Macroglobulinemia Program at the Dana-Farber Cancer Institute. Bob’s current research interests include helping to discover novel correlations among laboratory results, medical history, and burden of disease within Waldenstrom’s macroglobulinemia. (Thank you to Julie Manning for a spot on characterization of her Dad.)
The list of publications that Bob has contributed to includes:
Ioakimidis L, Patterson CJ, Hunter ZR, Soumerai JD, Manning RJ, Turnbull B, Sheehy P, Treon SP. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar;9(1):62-6. PubMed PMID: 19362976.
Ciccarelli BT, Yang G, Hatjiharissi E, Ioakimidis L, Patterson CJ, Manning RJ, Xu L, Liu X, Tseng H, Gong P, Sun J, Zhou Y, Treon SP. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar;9(1):56-8. PubMed PMID: 19362974.
Leleu X, Hunter ZR, Xu L, Roccaro AM, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, Adamia S, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Br J Haematol. 2009 Apr;145(1):59-63. Epub 2009 Feb 6. PubMed PMID: 19220283.
Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, Adamia S, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, Roccaro AM, Ghobrial IM, Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood. 2009 Jan 15;113(3):626-34. Epub 2008 Nov 3. PubMed PMID: 18981296.
Ho AW, Hatjiharissi E, Ciccarelli BT, Branagan AR, Hunter ZR, Leleu X, Tournilhac O, Xu L, O'Connor K, Manning RJ, Santos DD, Chemaly M, Patterson CJ, Soumerai JD, Munshi NC, McEarchern JA, Law CL, Grewal IS, Treon SP. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood. 2008 Dec 1;112(12):4683-9. Epub 2008 Jan 23. PubMed PMID: 18216294; PubMed Central PMCID: PMC2597134.
Treon SP, Hatjiharissi E, Leleu X, Moreau AS, Roccaro A, Hunter ZR, Soumerai JD, Ciccarelli B, Xu L, Sacco A, Ngo HT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson CJ, Ghobrial I. Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S199-206. Review. PubMed PMID: 17877845.
Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly MA, Branagan AR, Manning RJ, Patterson CJ, Moreau AS, Ciccarelli B, Adamia S, Kriangkum J, Kutok JL, Tai YT, Zhang J, Pilarski LM, Anderson KC, Munshi N, Treon SP. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep;35(9):1366-75. PubMed PMID: 17761288.
Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007 Oct 1;110(7):2561-4. Epub 2007 May 2. PubMed PMID: 17475906; PubMed Central PMCID: PMC1988936.
Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, Manning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC, Tai YT, Anderson KC, Treon SP. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma. 2006 May;6(6):478-83. PubMed PMID: 16796779. |
<< Back
|
|
